Trials
1 active
3 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Ischemic Cardiomyopathy, Heart Failure
- Main trialPhase 2
- “This is a prospective, multicenter, randomized, open-label, parallel-controlled Phase IIb study to investigate the diagnostic-prognostic utility of XTR003 Injection integrated with 18F-FDG as an exploratory clinical trial. A total of 40-60 patients will be enrolled and randomized into two study groups as: fasting XTR003/18F-FDG group and glucose-loaded group at a 1:1 ratio. Each group will receive resting myocardial perfusion imaging (MPI) combined with metabolic PET imaging to evaluate myocardial metabolic activity and myocardial viability. Segmental perfusion abnormality, metabolic activity…”In the company’s words, NCT07443696 on ClinicalTrials.gov
Other drugs for Heart Failure
- Balcinrenone/ dapagliflozinAstraZeneca · Phase 3
- DapagliflozinAstraZeneca · Phase 3
- HiCM-188HELP Therapeutics Co., Ltd. · Phase 3
- Omecamtiv MecarbilCytokinetics · Phase 3
- InclisiranNovartis · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
Coming up1
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovCompletion date moved: 2026-08 to 2026-12-31 · ClinicalTrials.gov NCT07443696
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2026 | PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy | |
| Phase 2Completed | 4 Mar 2023 | XTR003 PET Radiotracer for the Detection of Viable Myocardium | |
| Phase 1Completed | 27 Aug 2021 | A Phase I Study to Evaluate XTR003 in Healthy Chinese Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026